Skip to main content
. Author manuscript; available in PMC: 2018 Jan 24.
Published in final edited form as: ACS Nano. 2016 Dec 16;11(1):335–346. doi: 10.1021/acsnano.6b05910

Figure 5.

Figure 5

pRNA–HER2apt–siMED1 nanoparticles inhibited HER2-overexpressing breast tumor growth in vivo. (A) BT474 orthotopic xenograft mouse models were treated with control pRNA–HER2apt–siScram or pRNA–HER2apt–siMED1 (4 mg/kg) once a week, in combination with vehicle or tamoxifen (TAM, 0.5 mg/mice/day) 5 days per week. Tumor sizes were measured every 3 days. (B) After 3 weeks, mice were i.p. injected with d-luciferin, and representative in vivo images of BT474 tumors were recorded using IVIS Lumina imaging system. (C and D) Average weight of the tumors excised at the end of the treatment (C) and the representative photos of tumors (D). (E-G) MED1 expression in the BT474 tumors was examined using IHC staining (E and F) and immunoblotting (G). (H and I) The expression of Ki-67 in tumor tissues was analyzed using IHC staining (H), and the percentage of Ki-67 positive cells was counted (I). Scale bar: 100 μm.